SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com -- Oxford BioMedica (LON:OXB) on Monday delivered strong first-half results with revenues increasing 38-44% year-over-year to £70-73 million, according to a trading update.
The gene and cell therapy contract development and manufacturing organization (CDMO) reaffirmed its full-year 2025 guidance of £160-170 million in revenue with a low single-digit positive EBITDA margin.
The company has already contracted £165 million in revenue, up from £103 million in the same period last year.
Commercial momentum accelerated significantly during the first half, with new client orders totaling £149 million, more than double the £56 million secured in the first half of 2024.
This strong order intake has increased the company’s revenue backlog to £222 million as of June 30, up from £150 million at the end of 2024.
Oxford BioMedica’s multi-site strategy is progressing well, with lentiviral manufacturing capabilities now active across the UK, US, and France.
In June, the company completed its acquisition of the remaining 10% of OXB US, fully integrating the site into its global network.
The company is expanding capacity through GMP suite refits and lab automation in the UK, while transferring AAV platform technology to its French facilities to meet growing client demand, particularly for late-stage programs.
Oxford BioMedica will report its detailed interim results on September 23, followed by a Capital Markets Day on October 15.
The company’s shares currently trade at £3.83, with RBC analysts setting a price target of £5.66, representing 48% potential upside.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.